<DOC>
	<DOCNO>NCT01520753</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial compare two different active treatment regimen biphasic insulin aspart subject type 2 diabetes .</brief_summary>
	<brief_title>Comparison Two Biphasic Insulin Aspart Treatments Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Type 2 diabetes Duration diabetes longer 12 month Body mass index ( BMI ) 35.0 kg/m^2 HbA1c 11.0 % Treatment BHI ( biphasic human insulin ) 20 30 twice daily least three month last month sole antidiabetic treatment ( i.e. , additional oral hypoglycaemic medication daily use shortacting insulin supplement ) Current treatment agent affect glucose metabolism History drug alcohol dependence Impaired hepatic function Impaired renal function Cardiac disease Proliferative retinopathy Recurrent severe hypoglycaemia advance neuropathy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>